WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
US20140031250A1
(en)
|
2010-10-07 |
2014-01-30 |
David Tsai Ting |
Biomarkers of Cancer
|
CN103502448B
(zh)
|
2010-11-12 |
2017-03-29 |
Gen9股份有限公司 |
核酸合成的方法和设备
|
WO2012064975A1
(en)
|
2010-11-12 |
2012-05-18 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
WO2013012674A1
(en)
|
2011-07-15 |
2013-01-24 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
WO2013032850A2
(en)
|
2011-08-26 |
2013-03-07 |
Gen9, Inc. |
Compositions and methods for high fidelity assembly of nucleic acids
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
EP4001427A1
(en)
|
2012-04-24 |
2022-05-25 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
DE202013012242U1
(de)
|
2012-05-25 |
2016-02-02 |
Emmanuelle Charpentier |
Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
CN113512577A
(zh)
|
2012-06-25 |
2021-10-19 |
Gen9股份有限公司 |
用于核酸组装和高通量测序的方法
|
EP2906602B1
(en)
*
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
PL3138910T3
(pl)
|
2012-12-06 |
2018-01-31 |
Sigma Aldrich Co Llc |
Oparta na CRISPR modyfikacja i regulacja genomu
|
SG10201707569YA
(en)
|
2012-12-12 |
2017-10-30 |
Broad Inst Inc |
Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
|
EP3434776A1
(en)
|
2012-12-12 |
2019-01-30 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
EP3919505B1
(en)
|
2013-01-16 |
2023-08-30 |
Emory University |
Uses of cas9-nucleic acid complexes
|
WO2014124284A1
(en)
|
2013-02-07 |
2014-08-14 |
The General Hospital Corporation |
Tale transcriptional activators
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
WO2014150624A1
(en)
|
2013-03-14 |
2014-09-25 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
KR102210319B1
(ko)
|
2013-03-15 |
2021-02-01 |
더 제너럴 하스피탈 코포레이션 |
특정 게놈 좌위에 대한 유전적 및 후성적 조절 단백질의 rna-안내 표적화
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
WO2014165825A2
(en)
*
|
2013-04-04 |
2014-10-09 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
US20140356956A1
(en)
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
WO2014197568A2
(en)
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guideded transcriptional regulation
|
BR112015031608A2
(pt)
|
2013-06-17 |
2017-08-22 |
Massachusetts Inst Technology |
Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos
|
AU2014281026B2
(en)
|
2013-06-17 |
2020-05-28 |
Massachusetts Institute Of Technology |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
RU2716421C2
(ru)
|
2013-06-17 |
2020-03-11 |
Те Брод Инститьют Инк. |
Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов
|
KR20160034901A
(ko)
|
2013-06-17 |
2016-03-30 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물
|
WO2014204727A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
EP3611268A1
(en)
|
2013-08-22 |
2020-02-19 |
E. I. du Pont de Nemours and Company |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
DE202014010413U1
(de)
|
2013-09-18 |
2015-12-08 |
Kymab Limited |
Zellen und Organismen
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
DK3066201T3
(en)
|
2013-11-07 |
2018-06-06 |
Editas Medicine Inc |
CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES
|
EP3080266B1
(en)
*
|
2013-12-12 |
2021-02-03 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
SG10201804974RA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
BR112016013201B1
(pt)
|
2013-12-12 |
2023-01-31 |
The Broad Institute, Inc. |
Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
KR20160102056A
(ko)
|
2013-12-26 |
2016-08-26 |
더 제너럴 하스피탈 코포레이션 |
멀티플렉스 가이드 rna
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
PL3105328T3
(pl)
|
2014-02-11 |
2020-10-19 |
The Regents Of The University Of Colorado, A Body Corporate |
Umożliwiana przez CRISPR multipleksowa modyfikacja genomu
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
JP2017512481A
(ja)
|
2014-04-08 |
2017-05-25 |
ノースカロライナ ステート ユニバーシティーNorth Carolina State University |
Crispr関連遺伝子を用いた、rna依存性の転写抑制のための方法および組成物
|
US10066241B2
(en)
|
2014-05-30 |
2018-09-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
ES2888976T3
(es)
|
2014-06-23 |
2022-01-10 |
Massachusetts Gen Hospital |
Identificación no sesgada pangenómica de DSBs evaluada por secuenciación (GUIDE-Seq.)
|
US20150376586A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
US20170198268A1
(en)
*
|
2014-07-09 |
2017-07-13 |
Gen9, Inc. |
Compositions and Methods for Site-Directed DNA Nicking and Cleaving
|
US10676754B2
(en)
|
2014-07-11 |
2020-06-09 |
E I Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
US10077453B2
(en)
|
2014-07-30 |
2018-09-18 |
President And Fellows Of Harvard College |
CAS9 proteins including ligand-dependent inteins
|
US9932566B2
(en)
|
2014-08-07 |
2018-04-03 |
Agilent Technologies, Inc. |
CIS-blocked guide RNA
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
RU2017112324A
(ru)
|
2014-09-12 |
2018-10-15 |
Пайонир Хай-Бред Интернэшнл, Инк. |
Создание сайтов сайт-специфической интеграции для сложных локусов признаков в кукурузе и сое, а также способы применения
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
WO2016054106A1
(en)
*
|
2014-09-29 |
2016-04-07 |
The Regents Of The University Of California |
SCAFFOLD RNAs
|
CA2963693A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
EP3215617B1
(en)
|
2014-11-07 |
2024-05-08 |
Editas Medicine, Inc. |
Systems for improving crispr/cas-mediated genome-editing
|
CN107109486B
(zh)
*
|
2014-11-14 |
2021-08-13 |
基础科学研究院 |
用于检测基因组中遗传剪刀的脱靶位点的方法
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
CN104531633A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
Cas9-scForkI融合蛋白及其应用
|
CN107109422B
(zh)
*
|
2014-11-19 |
2021-08-13 |
基础科学研究院 |
使用由两个载体表达的拆分的Cas9的基因组编辑
|
JP7068821B2
(ja)
|
2014-12-03 |
2022-05-17 |
アジレント・テクノロジーズ・インク |
化学修飾を有するガイドrna
|
CN107208079B
(zh)
*
|
2014-12-05 |
2021-06-29 |
应用干细胞有限公司 |
整合转基因的位点定向crispr/重组酶组合物和方法
|
WO2016094679A1
(en)
|
2014-12-10 |
2016-06-16 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
EP3230452A1
(en)
*
|
2014-12-12 |
2017-10-18 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
EP3985115A1
(en)
*
|
2014-12-12 |
2022-04-20 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
US20180179523A1
(en)
*
|
2014-12-18 |
2018-06-28 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
CN107208096B
(zh)
*
|
2014-12-18 |
2021-02-12 |
综合基因技术公司 |
基于crispr的组合物和使用方法
|
US10190106B2
(en)
*
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
EP3250689B1
(en)
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
LT3250691T
(lt)
|
2015-01-28 |
2023-09-11 |
Caribou Biosciences, Inc. |
Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
BR122023024788A2
(pt)
|
2015-02-18 |
2023-12-26 |
Iowa State University Research Foundation, Inc. |
Genoma de planta geneticamente modificado para aumentar o teor de proteína e resistência a um agente patogênico ou a uma praga
|
EP3858990A1
(en)
|
2015-03-03 |
2021-08-04 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
US10450576B2
(en)
|
2015-03-27 |
2019-10-22 |
E I Du Pont De Nemours And Company |
Soybean U6 small nuclear RNA gene promoters and their use in constitutive expression of small RNA genes in plants
|
CN107787367B
(zh)
|
2015-04-06 |
2021-10-26 |
里兰斯坦福初级大学理事会 |
用于crispr/cas介导的基因调控的化学修饰的引导rna
|
JP2018522249A
(ja)
|
2015-04-24 |
2018-08-09 |
エディタス・メディシン、インコーポレイテッド |
Cas9分子/ガイドrna分子複合体の評価
|
WO2016182959A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
US20160346360A1
(en)
|
2015-05-29 |
2016-12-01 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
EA201792663A1
(ru)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
JP6961494B2
(ja)
*
|
2015-06-10 |
2021-11-05 |
フイルメニツヒ ソシエテ アノニムFirmenich Sa |
匂い物質および芳香の受容体をスクリーニングするための細胞株
|
US20160362705A1
(en)
|
2015-06-12 |
2016-12-15 |
Lonza Walkersville, Inc. |
Methods for Nuclear Reprogramming Using Synthetic Transcription Factors
|
EP3307872B1
(en)
|
2015-06-15 |
2023-09-27 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
CA2989830A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute, Inc. |
Crispr enzyme mutations reducing off-target effects
|
AU2016285724A1
(en)
|
2015-06-29 |
2017-11-16 |
Ionis Pharmaceuticals, Inc. |
Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
|
WO2017004279A2
(en)
*
|
2015-06-29 |
2017-01-05 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
US11479793B2
(en)
*
|
2015-07-15 |
2022-10-25 |
Rutgers, The State University Of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
CA2993431A1
(en)
|
2015-07-31 |
2017-02-09 |
Regents Of The University Of Minnesota |
Nuclease based knockouts of immunological checkpoint genes in immune cells
|
WO2017023974A1
(en)
*
|
2015-08-03 |
2017-02-09 |
President And Fellows Of Harvard College |
Cas9 genome editing and transcriptional regulation
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
MX2018002339A
(es)
|
2015-08-25 |
2018-12-19 |
Univ Duke |
Composiciones y metodos de mejora de la especificidad en ingenieria genomica usando endonucleasas guiadas por arn.
|
WO2017040348A1
(en)
*
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US10526590B2
(en)
|
2015-08-31 |
2020-01-07 |
Agilent Technologies, Inc. |
Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
JP2018530536A
(ja)
*
|
2015-09-11 |
2018-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
ヌクレアーゼDSBの完全照合およびシーケンシング(FIND−seq)
|
WO2017053879A1
(en)
|
2015-09-24 |
2017-03-30 |
Editas Medicine, Inc. |
Use of exonucleases to improve crispr/cas-mediated genome editing
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
EP3356526B1
(en)
|
2015-09-30 |
2021-08-25 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
|
MX2018004264A
(es)
*
|
2015-10-06 |
2018-11-09 |
Inst Basic Science |
Metodo para producir plantas completas a partir de protoplastos.
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
IL310721A
(en)
|
2015-10-23 |
2024-04-01 |
Harvard College |
Nucleobase editors and their uses
|
ES2699848T3
(es)
|
2015-10-23 |
2019-02-13 |
Caribou Biosciences Inc |
Acido nucleico CRISPR clase 2 de tipo cruzado modificado que se dirige a ácidos nucleicos
|
CN108474022A
(zh)
|
2015-11-03 |
2018-08-31 |
哈佛学院董事及会员团体 |
用于包含三维核酸的基质容积成像的设备和方法
|
US11566052B2
(en)
|
2015-11-11 |
2023-01-31 |
Lonza Ltd. |
CRISPR-associated (Cas) proteins with reduced immunogenicity
|
WO2017087979A1
(en)
|
2015-11-20 |
2017-05-26 |
Washington University |
Preparative electrophoretic method for targeted purification of genomic dna fragments
|
EP3382018B1
(en)
*
|
2015-11-25 |
2022-03-30 |
National University Corporation Gunma University |
Dna methylation editing kit and dna methylation editing method
|
US11345931B2
(en)
|
2015-12-14 |
2022-05-31 |
President And Fellows Of Harvard College |
Cas discrimination using tuned guide RNA
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
BR112018013065A2
(pt)
*
|
2015-12-28 |
2018-12-11 |
Intellia Therapeutics Inc |
composições e métodos para o tratamento de hemoglobinopatias
|
JP7012645B2
(ja)
|
2016-01-11 |
2022-01-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
キメラタンパク質および免疫治療の方法
|
IL304088A
(en)
|
2016-01-11 |
2023-08-01 |
Univ Leland Stanford Junior |
Systems containing chimeric proteins and their uses for controlling gene expression
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
CN114196746A
(zh)
|
2016-02-10 |
2022-03-18 |
密歇根大学董事会 |
核酸的检测
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
MX2018011170A
(es)
|
2016-03-15 |
2019-05-16 |
Apse Inc |
Metodos y composiciones para incrementar la produccion de arn bicatenario.
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
CN106701765A
(zh)
*
|
2016-04-11 |
2017-05-24 |
广东赤萌医疗科技有限公司 |
用于hiv感染治疗的多核苷酸及其制备药物应用
|
WO2017180915A2
(en)
*
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
CA3022290A1
(en)
|
2016-04-25 |
2017-11-02 |
President And Fellows Of Harvard College |
Hybridization chain reaction methods for in situ molecular detection
|
CN107326046A
(zh)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
一种提高外源基因同源重组效率的方法
|
RU2745563C2
(ru)
|
2016-05-20 |
2021-03-29 |
Регенерон Фармасьютикалс, Инк. |
Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
|
US20190100732A1
(en)
|
2016-06-02 |
2019-04-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Assay for the removal of methyl-cytosine residues from dna
|
CA3209273A1
(en)
*
|
2016-06-02 |
2017-12-07 |
Sigma-Aldrich Co. Llc |
Using programmable dna binding proteins to enhance targeted genome modification
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
JP6940117B2
(ja)
*
|
2016-06-15 |
2021-09-22 |
ツールゲン インコーポレイテッドToolgen Incorporated |
オンターゲットおよびオフターゲットの多標的システムを用いた標的特異的ヌクレアーゼをスクリーニングするための方法およびその利用
|
LT3474669T
(lt)
|
2016-06-24 |
2022-06-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Barkodu pažymėtų kombinatorinių bibliotekų generavimo būdai
|
US11471462B2
(en)
|
2016-06-27 |
2022-10-18 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
WO2018005117A1
(en)
*
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Storage through iterative dna editing
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
EP3484870B1
(en)
*
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
US20230151341A1
(en)
*
|
2016-07-13 |
2023-05-18 |
Qihan Chen |
Method for specifically editing genomic dna and application thereof
|
CN109790527A
(zh)
*
|
2016-07-26 |
2019-05-21 |
通用医疗公司 |
普氏菌属和弗朗西斯氏菌属的CRISPR1(Cpf1)的变体
|
CN109789185A
(zh)
*
|
2016-07-28 |
2019-05-21 |
基础科学研究院 |
用于治疗眼部疾病的含cas9蛋白和向导rna的药物组合物
|
KR20190041476A
(ko)
|
2016-07-29 |
2019-04-22 |
리제너론 파마슈티칼스 인코포레이티드 |
C-절단된 피브릴린-1의 발현을 유도하는 돌연변이를 포함하는 마우스
|
EP3494220A1
(en)
|
2016-08-02 |
2019-06-12 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
CA3032699A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harvard College |
Adenosine nucleobase editors and uses thereof
|
AU2017308889B2
(en)
|
2016-08-09 |
2023-11-09 |
President And Fellows Of Harvard College |
Programmable Cas9-recombinase fusion proteins and uses thereof
|
WO2018030457A1
(ja)
|
2016-08-10 |
2018-02-15 |
武田薬品工業株式会社 |
真核細胞のゲノムの標的部位を改変する方法及び標的部位における検出対象核酸配列の存在又は非存在を検出する方法
|
EP3502261A4
(en)
*
|
2016-08-19 |
2020-07-15 |
Toolgen Incorporated |
ARTIFICIALLY MODIFIED ANGIOGENESIS REGULATION SYSTEM
|
WO2018035495A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Whitehead Institute For Biomedical Research |
Methods of editing dna methylation
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
KR102455249B1
(ko)
|
2016-08-24 |
2022-10-17 |
상가모 테라퓨틱스, 인코포레이티드 |
가공된 표적 특이적 뉴클레아제
|
CN110325635B
(zh)
|
2016-08-24 |
2023-12-26 |
桑格摩生物治疗股份有限公司 |
使用工程化的核酸酶调控基因表达
|
US20190255106A1
(en)
*
|
2016-09-07 |
2019-08-22 |
Flagship Pioneering Inc. |
Methods and compositions for modulating gene expression
|
WO2018048194A1
(ko)
*
|
2016-09-07 |
2018-03-15 |
울산대학교 산학협력단 |
dCas9 단백질 및 표적 핵산 서열에 결합하는 gRNA를 이용한 핵산 검출의 민감도 및 특이도 향상용 조성물 및 방법
|
EP3523426A4
(en)
|
2016-09-30 |
2020-01-22 |
The Regents of The University of California |
RNA GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHOD FOR USE THEREOF
|
CN107880132B
(zh)
*
|
2016-09-30 |
2022-06-17 |
北京大学 |
一种融合蛋白及使用其进行同源重组的方法
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
KR20230164759A
(ko)
|
2016-10-07 |
2023-12-04 |
인티그레이티드 디엔에이 테크놀로지스 아이엔씨. |
S. 피오게네스 cas9 돌연변이 유전자 및 이에 의해 암호화되는 폴리펩티드
|
CA3040481A1
(en)
|
2016-10-14 |
2018-04-19 |
The General Hospital Corporation |
Epigenetically regulated site-specific nucleases
|
CN110214180A
(zh)
|
2016-10-14 |
2019-09-06 |
哈佛大学的校长及成员们 |
核碱基编辑器的aav递送
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
US20180282722A1
(en)
*
|
2016-11-21 |
2018-10-04 |
Massachusetts Institute Of Technology |
Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
|
EP3545085A4
(en)
|
2016-11-22 |
2020-10-28 |
Integrated Dna Technologies, Inc. |
CRISPR / CPF1 SYSTEMS AND METHODS
|
BR112019011509A2
(pt)
|
2016-12-08 |
2020-01-28 |
Intellia Therapeutics Inc |
rnas guias modificados
|
WO2018111947A1
(en)
|
2016-12-12 |
2018-06-21 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
JP7317706B2
(ja)
|
2016-12-14 |
2023-07-31 |
リガンダル インコーポレイテッド |
核酸およびタンパク質ペイロード送達のための方法および組成物
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
US20190382751A1
(en)
*
|
2016-12-28 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and uses thereof
|
CN110520163A
(zh)
|
2017-01-05 |
2019-11-29 |
新泽西鲁特格斯州立大学 |
独立于dna双链断裂的靶向基因编辑平台及其用途
|
FI3565891T3
(fi)
|
2017-01-09 |
2023-07-04 |
Whitehead Inst Biomedical Res |
Menetelmiä geeniekspression muuttamiseksi häiritsemällä säätelysilmukoita muodostavia transkriptiotekijämultimeerejä
|
WO2018135838A2
(ko)
*
|
2017-01-17 |
2018-07-26 |
기초과학연구원 |
Dna 단일가닥 절단에 의한 염기 교정 비표적 위치 확인 방법
|
CA3049980A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
WO2018148511A1
(en)
|
2017-02-10 |
2018-08-16 |
Zymergen Inc. |
A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
|
US11518991B2
(en)
|
2017-02-24 |
2022-12-06 |
Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
CN110914426A
(zh)
|
2017-03-23 |
2020-03-24 |
哈佛大学的校长及成员们 |
包含核酸可编程dna结合蛋白的核碱基编辑器
|
CN108660161B
(zh)
*
|
2017-03-31 |
2023-05-09 |
中国科学院脑科学与智能技术卓越创新中心 |
基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法
|
US11867661B2
(en)
|
2017-04-07 |
2024-01-09 |
Sage Science, Inc. |
Systems and methods for detection of genetic structural variation using integrated electrophoretic DNA purification
|
JP7379160B2
(ja)
|
2017-04-21 |
2023-11-14 |
ザ ジェネラル ホスピタル コーポレイション |
CRISPR-Cpf1を使用する誘導性で調整可能な多重ヒト遺伝子制御
|
CA3059956A1
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
WO2018218166A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
SG11201911597YA
(en)
|
2017-06-05 |
2020-01-30 |
Regeneron Pharma |
B4galt1 variants and uses thereof
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
WO2018232114A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
CA3067382A1
(en)
|
2017-06-15 |
2018-12-20 |
The Regents Of The University Of California |
Targeted non-viral dna insertions
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
EP3645021A4
(en)
|
2017-06-30 |
2021-04-21 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
CN111183226A
(zh)
*
|
2017-07-11 |
2020-05-19 |
西格马-奥尔德里奇有限责任公司 |
使用核小体相互作用蛋白结构域来增强靶向基因组修饰
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
AU2018309714A1
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharmaceuticals, Inc. |
Assessment of CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
|
AU2018309716A1
(en)
|
2017-07-31 |
2020-01-16 |
Regeneron Pharmaceuticals, Inc. |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
CN111182790A
(zh)
|
2017-07-31 |
2020-05-19 |
瑞泽恩制药公司 |
Crispr报告体非人类动物及其用途
|
US11897920B2
(en)
|
2017-08-04 |
2024-02-13 |
Peking University |
Tale RVD specifically recognizing DNA base modified by methylation and application thereof
|
WO2019028686A1
(zh)
|
2017-08-08 |
2019-02-14 |
北京大学 |
基因敲除方法
|
US11286468B2
(en)
*
|
2017-08-23 |
2022-03-29 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases with altered PAM specificity
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
EP4276185A3
(en)
|
2017-09-29 |
2024-02-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
WO2019075197A1
(en)
|
2017-10-11 |
2019-04-18 |
The General Hospital Corporation |
METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
|
AU2018352592A1
(en)
|
2017-10-16 |
2020-06-04 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
CN107602707B
(zh)
*
|
2017-10-17 |
2021-04-23 |
湖北大学 |
一种特异性调节枯草芽孢杆菌外源基因表达的dcas9-ω融合蛋白及其应用
|
BR112020008201A2
(pt)
|
2017-10-27 |
2020-10-06 |
The Regents Of The University Of California |
substituição-alvo de receptores de células t endógenos
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
US20210180059A1
(en)
|
2017-11-16 |
2021-06-17 |
Astrazeneca Ab |
Compositions and methods for improving the efficacy of cas9-based knock-in strategies
|
US11293019B2
(en)
|
2017-12-22 |
2022-04-05 |
Gflas Life Sciences, Inc. |
Chimeric genome engineering molecules and methods
|
CN109504711A
(zh)
*
|
2018-02-14 |
2019-03-22 |
复旦大学 |
基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法
|
EP3755798A4
(en)
|
2018-02-19 |
2022-04-06 |
Yale University |
PHOSPHOPEPTIDE-ENCODED OLIGONUCLEOTIDE BANKS AND METHODS FOR DETECTING PHOSPHORYLATION-DEPENDENT MOLECULAR INTERACTIONS
|
CA3089331A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CN112313241A
(zh)
|
2018-04-17 |
2021-02-02 |
总医院公司 |
核酸结合、修饰、和切割试剂的底物偏好和位点的灵敏体外试验
|
GB2587970B
(en)
|
2018-04-19 |
2023-02-08 |
Univ California |
Compositions and methods for gene editing
|
CN108588123A
(zh)
*
|
2018-05-07 |
2018-09-28 |
南京医科大学 |
CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
CN110592141B
(zh)
*
|
2018-06-13 |
2023-07-07 |
中国科学院上海有机化学研究所 |
用于调控基因编辑效率的化合物及其应用
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
CN112513270A
(zh)
|
2018-07-13 |
2021-03-16 |
加利福尼亚大学董事会 |
基于逆转录转座子的递送媒介物及其使用方法
|
KR20210044795A
(ko)
|
2018-08-15 |
2021-04-23 |
지머젠 인코포레이티드 |
고 처리량 대사 공학에서 CRISPRi의 응용
|
KR20210049124A
(ko)
|
2018-08-23 |
2021-05-04 |
상가모 테라퓨틱스, 인코포레이티드 |
조작된 표적 특이적 염기 편집기
|
JP2021536250A
(ja)
|
2018-09-07 |
2021-12-27 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
改善されたヌクレアーゼのための組成物及び方法
|
EP3861120A4
(en)
|
2018-10-01 |
2023-08-16 |
North Carolina State University |
RECOMBINANT TYPE I CRISPR-CAS SYSTEM
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
KR20210104068A
(ko)
|
2018-12-14 |
2021-08-24 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
게놈 편집을 위한 신규한 crispr-cas 시스템
|
IL301193A
(en)
|
2018-12-20 |
2023-05-01 |
Regeneron Pharma |
Nuclease-mediated repeat expansion
|
WO2020148206A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
WO2020163396A1
(en)
|
2019-02-04 |
2020-08-13 |
The General Hospital Corporation |
Adenine dna base editor variants with reduced off-target rna editing
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
DE212020000516U1
(de)
|
2019-03-07 |
2022-01-17 |
The Regents of the University of California |
CRISPR-CAS-Effektorpolypeptide
|
JP7389135B2
(ja)
|
2019-03-18 |
2023-11-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タウ凝集に関連する遺伝的脆弱性を明らかにするためのcrispr/casドロップアウトスクリーニングプラットフォーム
|
JP7461368B2
(ja)
|
2019-03-18 |
2024-04-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タウの播種または凝集の遺伝的修飾因子を同定するためのcrispr/casスクリーニングプラットフォーム
|
AU2020242032A1
(en)
|
2019-03-19 |
2021-10-07 |
Massachusetts Institute Of Technology |
Methods and compositions for editing nucleotide sequences
|
AU2020256225A1
(en)
|
2019-04-03 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
|
IL286905B1
(en)
|
2019-04-04 |
2024-02-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
IL286917B
(en)
|
2019-04-04 |
2022-09-01 |
Regeneron Pharma |
Methods for scar-free insertion of targeted modifications into targeted vectors
|
CN113748205A
(zh)
|
2019-04-12 |
2021-12-03 |
阿斯利康(瑞典)有限公司 |
用于改进的基因编辑的组合物和方法
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
KR20220017939A
(ko)
|
2019-06-07 |
2022-02-14 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 알부민 좌위를 포함하는 비-인간 동물
|
AU2020290509A1
(en)
|
2019-06-14 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Models of tauopathy
|
EP3783104A1
(en)
*
|
2019-08-20 |
2021-02-24 |
Kemijski Institut |
Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
|
JP2022548031A
(ja)
|
2019-09-13 |
2022-11-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
脂質ナノ粒子によって送達されるcrispr/casシステムを使用する動物における転写調節
|
US11987791B2
(en)
|
2019-09-23 |
2024-05-21 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression
|
DK3812472T3
(da)
|
2019-10-21 |
2023-02-20 |
Univ Freiburg Albert Ludwigs |
Virkelig uvildig in vitro-undersøgelse til profilering af off-target-aktivitet af en eller flere målspecifikke programmerbare nukleaser i celler (abnoba-seq)
|
KR20220097414A
(ko)
|
2019-11-08 |
2022-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
|
US11331333B2
(en)
|
2019-11-08 |
2022-05-17 |
Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin |
Treatment of aberrant fibroblast proliferation
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
US20230042198A1
(en)
*
|
2019-11-25 |
2023-02-09 |
La Jolla Institute For Immunology |
Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions
|
IL293569A
(en)
|
2019-12-11 |
2022-08-01 |
Intellia Therapeutics Inc |
A modified rnas guide to gene editing
|
CN111088357B
(zh)
*
|
2019-12-31 |
2022-09-20 |
深圳大学 |
针对escc的肿瘤标志物及其应用
|
WO2021151085A2
(en)
*
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
US20210284978A1
(en)
*
|
2020-01-24 |
2021-09-16 |
The General Hospital Corporation |
Unconstrained Genome Targeting with near-PAMless Engineered CRISPR-Cas9 Variants
|
EP4114946A1
(en)
|
2020-03-04 |
2023-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US20230340435A1
(en)
*
|
2020-04-09 |
2023-10-26 |
Verve Therapautics, Inc. |
Base editing of angptl3 and methods of using same for treatment of disease
|
US20230193212A1
(en)
|
2020-05-06 |
2023-06-22 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
CA3177481A1
(en)
|
2020-05-08 |
2021-11-11 |
David R. Liu |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
JP2023526007A
(ja)
|
2020-05-13 |
2023-06-20 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
β-ヘモグロビン異常症の処置のための塩基編集アプローチ
|
WO2021246165A1
(ja)
*
|
2020-06-03 |
2021-12-09 |
国立大学法人広島大学 |
Oasis遺伝子の脱メチル化のための核酸及びそれを用いた脱メチル化方法
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
IL300374A
(en)
|
2020-08-11 |
2023-04-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
A method for treating diseases related to WWOX
|
KR20230082676A
(ko)
|
2020-10-13 |
2023-06-08 |
쌍트르 나시오날 드 라 르쉐르쉐 싸이엉띠피끄(쎄.엔.에르.에스.) |
표적-항균-플라스미드 조합 접합 및 crispr/cas 시스템 및 그의 용도
|
RU2762831C1
(ru)
*
|
2020-10-26 |
2021-12-23 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
Молекула рнк-проводника для геномного редактирования протомоторной области гена vrn-a1 однодольных зерновых с применением системы crispr/cas9
|
CN112430622A
(zh)
*
|
2020-10-26 |
2021-03-02 |
扬州大学 |
一种FokI和dCpf1融合蛋白表达载体及其介导的定点基因编辑方法
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
KR20220082186A
(ko)
|
2020-12-10 |
2022-06-17 |
한세준 |
유,무선 충전이 가능한 보조배터리형 uv-led살균기
|
CA3207144A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
US20240052372A1
(en)
|
2021-02-25 |
2024-02-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
KR20220124652A
(ko)
|
2021-03-03 |
2022-09-14 |
중앙대학교 산학협력단 |
CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
|
CN113846019B
(zh)
*
|
2021-03-05 |
2023-08-01 |
海南师范大学 |
一种海洋微拟球藻靶向表观基因组遗传调控方法
|
EP4095243A1
(en)
|
2021-05-25 |
2022-11-30 |
European Molecular Biology Laboratory |
System for hybridization-based precision genome cleavage and editing, and uses thereof
|
JP2024518793A
(ja)
|
2021-05-27 |
2024-05-02 |
アストラゼネカ・アクチエボラーグ |
向上した安定性を有するcas9エフェクタータンパク質
|
EP4352225A1
(en)
|
2021-06-10 |
2024-04-17 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
CA3229450A1
(en)
|
2021-08-20 |
2023-02-23 |
Wisconsin Alumni Research Foundation |
Nonviral generation of genome edited chimeric antigen receptor t cells
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
WO2023069987A1
(en)
|
2021-10-20 |
2023-04-27 |
University Of Rochester |
Rejuvenation treatment of age-related white matter loss cross reference to related application
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
CA3237303A1
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
WO2023137472A2
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
WO2023141487A1
(en)
*
|
2022-01-20 |
2023-07-27 |
Inari Agriculture Technology, Inc. |
Improved soybean explant preparation and transformation
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023144104A1
(en)
|
2022-01-25 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of βeta-thalassemia
|
TW202332767A
(zh)
|
2022-02-02 |
2023-08-16 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗TfR:GAA及抗CD63:GAA插入
|
WO2023152351A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstream of meg3 in the dlk1/dio3 locus
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023217888A1
(en)
|
2022-05-10 |
2023-11-16 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from βeta-thalassemia
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024084025A1
(en)
|
2022-10-21 |
2024-04-25 |
Keygene N.V. |
Rna transfection in plant cells with modified rna
|
WO2024098002A1
(en)
|
2022-11-04 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
CN115820603A
(zh)
*
|
2022-11-15 |
2023-03-21 |
吉林大学 |
一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
|
CN116376975B
(zh)
*
|
2023-02-27 |
2024-05-14 |
中国科学院脑科学与智能技术卓越创新中心 |
激活异染色质基因的方法及应用
|